title: CD44v6 expression in patients with stage II or stage III sporadic colorectal cancer is superior to CD44 expression for predicting progression.
abstract: BACKGROUND
  Currently, it is difficult to predict the prognosis of patients exhibiting stage II or stage III colorectal cancer (CRC) and to identify those patients most likely to benefit from aggressive treatment. The current study was performed to examine the clinicopathological significance of CD44 and CD44v6 protein expression in these patients.
  
  
  METHODS
  We retrospectively investigated 187 consecutive patients who underwent surgery with curative intent for stage II to III CRC from 2007 to 2013 in the Beijing Civil Aviation Hospital. CD44 and CD44v6 protein expression levels were determined using immunohistochemistry and compared to the clinicopathological data.
  
  
  RESULTS
  Using immunohistochemical detection, CD44 expression was observed in 108 (57.75%) of the CRC patients; and its detection was significantly associated with greater invasion depth, lymph node metastasis, angiolymphatic invasion, and a more advanced pathological tumor-lymph node-metastasis (TNM) stage. CD44v6 expression was observed in 135 (72.19%) of the CRC patients; and its expression was significantly associated with a poorly differentiated histology, greater invasion depth, lymph node metastasis, angiolymphatic invasion, and a more advanced pathological TNM stage. Expression of CD44v6 was higher than that of CD44 in stage II and stage III sporadic CRC.
  
  
  CONCLUSIONS
  CD44v6 is a more useful marker for predicting a poor prognosis in stage II and stage III sporadic CRC as compared to CD44.
authors.affiliation: Department of Pathology, Beijing Civil Aviation Hospital 1 Gao Jing Jia, Chao Yang District, Beijing 100123, China.
authors.forename: L H
authors.initials: LH
authors.lastname: Zhao
authors.affiliation: Department of Pathology, Beijing Civil Aviation Hospital 1 Gao Jing Jia, Chao Yang District, Beijing 100123, China.
authors.forename: Q L
authors.initials: QL
authors.lastname: Lin
authors.affiliation: Department of Pathology, Beijing Civil Aviation Hospital 1 Gao Jing Jia, Chao Yang District, Beijing 100123, China.
authors.forename: J
authors.initials: J
authors.lastname: Wei
authors.affiliation: Department of Pathology, Beijing Civil Aviation Hospital 1 Gao Jing Jia, Chao Yang District, Beijing 100123, China.
authors.forename: Y L
authors.initials: YL
authors.lastname: Huai
authors.affiliation: Department of Pathology, Beijing Civil Aviation Hospital 1 Gao Jing Jia, Chao Yang District, Beijing 100123, China.
authors.forename: K J
authors.initials: KJ
authors.lastname: Wang
authors.affiliation: Department of Pathology, Beijing Civil Aviation Hospital 1 Gao Jing Jia, Chao Yang District, Beijing 100123, China.
authors.forename: H Y
authors.initials: HY
authors.lastname: Yan
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D015179:Colorectal Neoplasms / Q000473:pathology*; D018450:Disease Progression; D005260:Female; D006801:Humans; D018960:Hyaluronan Receptors / Q000096:biosynthesis*; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D020033:Protein Isoforms / Q000096:biosynthesis
chemical_list: D014408:Biomarkers, Tumor; C497483:CD44 protein, human; C112697:CD44v6 antigen; D018960:Hyaluronan Receptors; D020033:Protein Isoforms
keywords: CD44; CD44V6; colorectal cancer; immunohistochemistry